These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 31874110)

  • 21. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
    Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
    Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
    Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IκB Kinase α Is Required for Development and Progression of
    Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
    Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
    Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
    Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS.
    Pang X; Liu M
    Chin J Cancer; 2016 Oct; 35(1):92. PubMed ID: 27793187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.
    Wang CY; Guo ST; Wang JY; Liu F; Zhang YY; Yari H; Yan XG; Jin L; Zhang XD; Jiang CC
    Mol Cancer Ther; 2016 Mar; 15(3):448-59. PubMed ID: 26832792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
    Koppula P; Zhuang L; Gan B
    Protein Cell; 2021 Aug; 12(8):599-620. PubMed ID: 33000412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance.
    Huang Y; Dai Z; Barbacioru C; Sadée W
    Cancer Res; 2005 Aug; 65(16):7446-54. PubMed ID: 16103098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine/glutamate exchanger SLC7A11.
    Martin L; Gardner LB
    Oncogene; 2015 Aug; 34(32):4211-8. PubMed ID: 25399695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells.
    Xu Y; Zong S; Gao X; Zhang H; Wang B; Li P; Liu T; Li S
    Gene; 2019 Mar; 688():1-6. PubMed ID: 30415007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
    Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
    Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
    Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
    Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.
    Li HS; Liu CM; Wang Y
    Thorac Cancer; 2023 May; 14(15):1368-1382. PubMed ID: 37021520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
    Mohrherr J; Haber M; Breitenecker K; Aigner P; Moritsch S; Voronin V; Eferl R; Moriggl R; Stoiber D; Győrffy B; Brcic L; László V; Döme B; Moldvay J; Dezső K; Bilban M; Popper H; Moll HP; Casanova E
    Int J Cancer; 2019 Dec; 145(12):3376-3388. PubMed ID: 31407334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS
    Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer.
    Liu X; Olszewski K; Zhang Y; Lim EW; Shi J; Zhang X; Zhang J; Lee H; Koppula P; Lei G; Zhuang L; You MJ; Fang B; Li W; Metallo CM; Poyurovsky MV; Gan B
    Nat Cell Biol; 2020 Apr; 22(4):476-486. PubMed ID: 32231310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
    Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
    Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.